Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Lexicon Pharmaceutcl (LXRX)

Lexicon Pharmaceutcl (LXRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl's Antiproliferative Effects in Patients With Carcinoid Syndrome

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO's(telotristat ethyl) antiproliferative effects in patients with carcinoid syndrome that were presented at the American...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO(telotristat ethyl) will be presented at the American Society for Clinical Oncology (ASCO) 2020...

LXRX : 2.69 (-5.61%)
Neuroendocrine Carcinoma Market is projected to grow at a high 7.7% CAGR throughout 2017-2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 222.79 (+0.29%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.60 (+1.32%)
HCM : 26.19 (-4.59%)
LXRX : 2.69 (-5.61%)
NVS : 96.76 (+0.49%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

JPM : 135.81 (-1.22%)
LXRX : 2.69 (-5.61%)
Watch for Lexicon Pharmace to Potentially Rebound After Falling 4.99% Yesterday

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $4.08 to a high of $4.32. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $4.16...

LXRX : 2.69 (-5.61%)
Thinking about buying stock in Advanced Micro Devices, Best Buy, Canopy Growth Corp, Lexicon Pharmaceuticals, or Electrameccanica Vehicles?

InvestorsObserver issues critical PriceWatch Alerts for AMD, BBY, CGC, LXRX, and SOLO.

AMD : 53.28 (-6.97%)
BBY : 90.26 (-1.82%)
CGC : 21.88 (-1.93%)
SOLO : 2.03 (-1.47%)
LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista(TM)) in type 2 diabetes. The topline results are as follows:

LXRX : 2.69 (-5.61%)
Lexicon Pharmace Set to Possibly Rebound After Yesterday's Selloff of 1.20%

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $4.48 to a high of $4.64. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $4.65...

LXRX : 2.69 (-5.61%)
Neuroendocrine Carcinoma Market is Anticipated to Expand at a Healthy CAGR of 7.7% During the Forecast Period 2017 – 2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 222.79 (+0.29%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.60 (+1.32%)
HCM : 26.19 (-4.59%)
LXRX : 2.69 (-5.61%)
NVS : 96.76 (+0.49%)
TEVA : 13.19 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Implied Volatility Surging for Lexicon (LXRX) Stock Options

Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.

LXRX : 2.69 (-5.61%)
Cancer Drug Revenues Expected to be Largest Share in Pharma Market

One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8...

ONCY : 2.63 (+17.94%)
ONC.TO : 3.44 (+18.62%)
EPZM : 24.88 (-2.35%)
LXRX : 2.69 (-5.61%)
ABBV : 94.96 (+0.77%)
BMY : 65.63 (+0.71%)
Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211, a potent oral small molecule inhibitor of adaptor associated...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the Telotristat Ethyl for Advanced Biliary Tract Cancer, or TELE-ABC, study,...

LXRX : 2.69 (-5.61%)
Lexicon Pharmace Set to Possibly Rebound After Yesterday's Selloff of 11.41%

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $2.51 to a high of $3.18. Yesterday, the shares fell 11.4%, which took the trading range below the 3-day low of $3.46...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA's Office of New Drugs for Sotagliflozin in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and Administrative Affairs and Chief Financial Officer, will present at the...

LXRX : 2.69 (-5.61%)
Lexicon Pharmace Falls 3.08% on Heavy Volume: Watch For Potential Rebound

Lexicon Pharmace (NASDAQ:LXRX) traded in a range yesterday that spanned from a low of $3.58 to a high of $3.83. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $3.75...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the following conference:

LXRX : 2.69 (-5.61%)
Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

LXRX : 2.69 (-5.61%)
Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LXRX : 2.69 (-5.61%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -1.55 , SEDG -0.13 , THC +1.65 , TER -1.89 , LITE -3.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar